Askel Healthcare has opened a public crowdfunding campaign on Invesdor to support its mission of transforming knee joint repair and tackling osteoarthritis, a condition affecting more than 242 million people worldwide.
The company’s breakthrough solution, the COPLA® Cartilage implant, is a minimally invasive treatment that repairs damaged joints, restores mobility, and supports natural cartilage regeneration. In the ongoing Pilot Trial, all patients have been treated successfully with excellent results, highlighting the implant’s potential to delay or even prevent knee replacement surgery while quickly relieving pain and enabling long-term healing.
Funds raised in this round will complete the 20-patient Pilot Trial, prepare for a pivotal study of up to 250 patients, and move the company closer to EU and US regulatory approvals. Alongside the path to full market authorisation, the strong early results may also attract strategic partnerships or acquisitions, offering potential earlier exit opportunities for investors.
As part of the campaign, Askel Healthcare is offering 3.82–10.66% equity at EUR 9.60 per share, with a minimum investment of 40 shares. Investments of EUR 20,000 or more are made directly in the company and include a 15% discount. Interested investors are encouraged to contact CEO Virpi Muhonen directly at v.muhonen@askelhealthcare.com.
The subscription period runs from 16 September to 6 October 2025. Additional details can be found on the campaign website.
“Askel Healthcare is on a mission to keep people in motion. Knee pain is a leading cause of disability, keeping millions from the activities they love. Our COPLA® Cartilage implant works with the body’s own biology to repair the knee joint surface – restoring pain-free function and helping prevent further deterioration and osteoarthritis. Our human clinical trial has already delivered excellent results, with patients regaining function fast and sustaining their improvement. With the funding from this round, we will strengthen our clinical proof and take major steps toward market authorisations in the EU and US. We invite you to join us on this journey” says Virpi Muhonen, CEO of Askel Healthcare.
Two live investor webinars will be held during the campaign (no registration required):
- 23 September 2025 at 12:00 CET – Company Presentation
- 30 September 2025 at 12:00 CET – Q&A Session
For further information, please contact:
Virpi Muhonen, CEO, Askel Healthcare
Tel. +358 40 489 3840